BTIG Rates Guardant Health (GH) buy, $190 Price Target

BTIG analyst Mark Massaro reiterated a buy rating on Guardant Health, setting a $190 price target, a 26.64% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 1:00 PM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Guardant Health, Inc. ($GH) "buy" with a $190 price target on July 1, 2026.

Since the rating, $GH is down 8.6% after 1 week, down 5.1% after 1 month and down 7.1% to date (from the $170.77 close on Jul 1, 2026).

GH Guardant Health, Inc.

$158.60 +55.89% year to date

Daily close · Oct 16, 2026

Key Points

BTIG analyst Mark Massaro reiterated a buy rating on Guardant Health, Inc. (GH) with a target price of $190 as of July 1, 2026.
BTIG's $190 price target implies 26.64% upside from Guardant Health, Inc.'s ($GH) current $150.03 share price.
Shares of GH traded near $150.03 on Wednesday, with a market cap of approximately $19.89 billion and a beta of 1.619.
Guardant Health has seen institutional interest, with BlackRock and Vanguard among those adding to their positions.

Get $GH trade alerts by text

We text you when insiders, Congress or big funds trade $GH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures

BTIG analyst Mark Massaro has reiterated his buy rating on Guardant Health, Inc. (NasdaqGS: GH), maintaining a price target of $190. This reaffirmation came on July 1, 2026, as the stock traded near $150.03 on Wednesday.

Analyst rating track record

BTIG vs. the S&P 500

YTD return -20.12% hypothetical

All-time return +30.79% S&P 500 +41.27%

vs. S&P 500 -10.48% behind the index

Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On July 1, 2026, BTIG maintained its buy rating on Guardant Health with a $190 price target. Other analysts have also shown confidence in the stock. Guggenheim kept a buy rating with a $160 target on June 29, while Bernstein reinstated a buy rating with a $175 target on June 26. Barclays maintained a buy rating with a $150 target on June 24.

Guardant Health, Inc. Stock Down 9.6%

Shares of Guardant Health traded around $150.03 on Wednesday. The company has a market cap of approximately $19.89 billion. Its forward P/E ratio isn't meaningful as the company is not currently profitable. The stock's beta is 1.619, indicating it's more volatile than the market. Over the past year, the stock has ranged between $40.35 and $153.95, with a 50-day moving average of $112.55 and a 200-day moving average of $96.31.

12-month forecast

$GH price target

Guardant Health, Inc. daily closes and this analyst's $190 target. Not advice.

Insider Buying and Selling at Guardant Health, Inc.

Co-Chief Executive Officer Amirali Talasaz was active in recent insider transactions. On June 29, 2026, he sold 143,028 shares at an average price of $151.54 under a planned trading program. Earlier, on June 26, he sold 116,972 shares at an average price of $150.79, also under a planned program.

Other Institutional Activity in Guardant Health

Institutional investors have been active in Guardant Health. BlackRock, Inc. increased its holdings by 236,045 shares, bringing its total to 11,553,759 shares, valued at about $1.07 billion. Price T Rowe Associates added 1,387,611 shares, now holding 7,023,689 shares worth approximately $648.78 million. Vanguard Portfolio Management LLC opened a new position with 5,837,992 shares valued at about $539.26 million. Invesco Ltd. reduced its stake by 369,465 shares, now holding 4,946,469 shares valued at around $456.91 million.

About Guardant Health

Guardant Health, Inc. is a precision oncology company based in Palo Alto, California. It provides blood and tissue tests, focusing on cancer detection and treatment guidance. Its offerings include the Guardant360 CDx test for tumor mutation profiling and the Guardant Reveal test for early cancer detection. Dr. Helmy Eltoukhy leads the company, which employs approximately 2,490 people.

Bottom Line

BTIG's reaffirmation of a buy rating on Guardant Health, along with a $190 target, reflects ongoing confidence in the company's prospects. Investors often watch such analyst updates closely, though it's important to remember that these reports are based on past data and expectations.